Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Presents New Data on the Importance of Renin-Angiotensin-Aldosterone-System Inhibitor (RAASi) Therapy in Patients With Cardio-Renal Comorbidities at the Academy of Managed Care Pharmacy's 27th Annual Meeting

REDWOOD CITY, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database...
April 06, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2015, the compensation committee of the company's...
March 26, 2015 19:00 ET | Source: Relypsa, Inc.

Relypsa Presents Sub-Group Analysis From Phase 3 Study of Patiromer FOS in Patients With Advanced Chronic Kidney Disease at 2015 National Kidney Foundation Spring Clinical Meeting

REDWOOD CITY, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from a Phase 3 clinical program showing that Patiromer for...
March 18, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's...
March 16, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Highlights Multiple Presentations of Patiromer for Oral Suspension at the 2015 World Congress of Nephrology

REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today highlighted multiple data presentations of Patiromer for Oral Suspension (FOS)...
March 14, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session

Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D. Sponsored Panel at ACC Led by Prominent Thought Leader, Dr. Ileana L. Piña, will Review the Latest Data in Management...
March 11, 2015 16:10 ET | Source: Relypsa, Inc.

Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results

REDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31,...
March 04, 2015 16:30 ET | Source: Relypsa, Inc.

Relypsa Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on March 2, 2015, the compensation committee of the company's...
March 03, 2015 16:30 ET | Source: Relypsa, Inc.

Relypsa Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

REDWOOD CITY, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,485,000 shares of its common...
March 02, 2015 08:30 ET | Source: Relypsa, Inc.

Relypsa to Present at 27th Annual ROTH Conference

REDWOOD CITY, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Kristine M. Ball, senior vice president and chief financial officer, will present at the 27th...